These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 34060485)

  • 21. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
    Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
    Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma.
    Ning JF; Stanciu M; Humphrey MR; Gorham J; Wakimoto H; Nishihara R; Lees J; Zou L; Martuza RL; Wakimoto H; Rabkin SD
    Nat Commun; 2019 Jul; 10(1):2910. PubMed ID: 31266951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional inhibition of RECQL5 helicase elicits non-homologous end joining response and sensitivity of breast cancers to PARP inhibitor.
    Philip KT; Dutta K; Chakraborty S; Patro BS
    Int J Biochem Cell Biol; 2023 Aug; 161():106443. PubMed ID: 37392863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
    Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors.
    Liu Y; Xue R; Duan X; Shang X; Wang M; Wang F; Zhu L; Zhang L; Ge X; Zhao X; Guo H; Wang Z; Zhang L; Gao X; Shen A; Sheng Y; Qin Z
    Life Sci; 2023 Aug; 326():121790. PubMed ID: 37211345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
    Murai J; Feng Y; Yu GK; Ru Y; Tang SW; Shen Y; Pommier Y
    Oncotarget; 2016 Nov; 7(47):76534-76550. PubMed ID: 27708213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response.
    Wurster S; Hennes F; Parplys AC; Seelbach JI; Mansour WY; Zielinski A; Petersen C; Clauditz TS; Münscher A; Friedl AA; Borgmann K
    Oncotarget; 2016 Mar; 7(9):9732-41. PubMed ID: 26799421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
    Paes Dias M; Tripathi V; van der Heijden I; Cong K; Manolika EM; Bhin J; Gogola E; Galanos P; Annunziato S; Lieftink C; Andújar-Sánchez M; Chakrabarty S; Smith GCM; van de Ven M; Beijersbergen RL; Bartkova J; Rottenberg S; Cantor S; Bartek J; Ray Chaudhuri A; Jonkers J
    Mol Cell; 2021 Nov; 81(22):4692-4708.e9. PubMed ID: 34555355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
    Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F
    Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux.
    Pai Bellare G; Sankar Patro B
    Biochem Pharmacol; 2022 May; 199():115024. PubMed ID: 35367197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells.
    Verma P; Zhou Y; Cao Z; Deraska PV; Deb M; Arai E; Li W; Shao Y; Puentes L; Li Y; Patankar S; Mach RH; Faryabi RB; Shi J; Greenberg RA
    Nat Cell Biol; 2021 Feb; 23(2):160-171. PubMed ID: 33462394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB-Triggered SASP in Cancer-Associated Fibroblasts.
    Jin P; Li X; Xia Y; Li H; Li X; Yang ZY; Wang Z; Xu C; Fang T; Zhou D; Xiong X; Wang SY; Xu S; Gao Q
    Mol Cancer Ther; 2023 Apr; 22(4):447-458. PubMed ID: 36780236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
    Muvarak NE; Chowdhury K; Xia L; Robert C; Choi EY; Cai Y; Bellani M; Zou Y; Singh ZN; Duong VH; Rutherford T; Nagaria P; Bentzen SM; Seidman MM; Baer MR; Lapidus RG; Baylin SB; Rassool FV
    Cancer Cell; 2016 Oct; 30(4):637-650. PubMed ID: 27728808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors.
    Peng Y; Liao Q; Tan W; Peng C; Hu Z; Chen Y; Li Z; Li J; Zhen B; Zhu W; Li X; Yao Y; Song Q; Liu C; Qi X; He F; Pei H
    Nat Commun; 2019 Mar; 10(1):1224. PubMed ID: 30874560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors.
    Zhou J; Gelot C; Pantelidou C; Li A; Yücel H; Davis RE; Färkkilä A; Kochupurakkal B; Syed A; Shapiro GI; Tainer JA; Blagg BSJ; Ceccaldi R; D'Andrea AD
    Nat Cancer; 2021 Jun; 2(6):598-610. PubMed ID: 34179826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
    Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.
    Chan N; Pires IM; Bencokova Z; Coackley C; Luoto KR; Bhogal N; Lakshman M; Gottipati P; Oliver FJ; Helleday T; Hammond EM; Bristow RG
    Cancer Res; 2010 Oct; 70(20):8045-54. PubMed ID: 20924112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells.
    Wang H; Zhang S; Song L; Qu M; Zou Z
    Oncogene; 2020 Apr; 39(14):2905-2920. PubMed ID: 32029902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.